Top Markets
#1 Songbird Songbird +15.68%
#2 TENDIES TENDIES +9.42%
#3 DAPPOS DAPPOS +9.36%
#4 pipedog pipedog +8.37%
#5 Prom Prom +7.95%
#6 Helium Helium +7.35%
#7 Collector Crypt Collector Crypt +6.69%
#8 MarsCoin MarsCoin +6.62%
#9 Cryptopia Cryptopia +5.90%
#10 Moolah Moolah +5.25%
Coin of the day
Songbird Songbird
Settings
Language
ENGLISH
Currency
USD
Theme
Novogene Co., Ltd. Novogene Co., Ltd.

Novogene Co., Ltd.

688315
Rank in Stocks #9857
Novogene Co., Ltd. is a global provider of comprehensive genomic services and... Novogene Co., Ltd. is a global provider of comprehensive genomic services and advanced solutions. Its offerings span a wide array of genomic applications, including human, animal, plant, and microbial genome sequencing, alongside gene regulation and single-cell sequencing technologies. The company also specializes in cancer genomic profiling, whole exome sequencing (including clinical-grade versions), and FFPE RNA sequencing. Furthermore, Novogene develops proprietary tools such as NovoFocus, a next-generation sequencing (NGS)-based companion diagnostic for PARP inhibitor treatments, and NovoNeoantigen, a bioinformatics pipeline that identifies cancer neoantigens by analyzing whole exome and whole transcriptome sequencing data from matched tumor and normal samples. In a strategic collaboration, Novogene partners with Hummingbird Bioscience Pte. Ltd. to aid in the advancement of HMBD-001. This investigational anti-HER3 antibody is being assessed for its potential to treat diverse cancer types, notably those driven by NRG1-fusion. Established in 2011, Novogene Co., Ltd. operates from its headquarters in Beijing, China.
Share Price
$2.25
Last synced: 2026-08-28
Market Cap
$936.66M
Change (1 day)
-3.18%
Change (1 year)
3.07%
Country
CN
Trade Novogene Co., Ltd. (688315)

Category

Healthcare
P/E ratio for Novogene Co., Ltd. (688315)
P/E ratio as of 2026 TTM: 0
According to Novogene Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Novogene Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.